Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06770764 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors, sponsored by Trutino Biosciences.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT06770764 is a Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors that is actively recruiting participants, run by Trutino Biosciences. The registered enrollment target is 50 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06770764, a Phase 1 study of Advanced Solid Tumors and Metastatic Solid Tumors, is actively recruiting participants, sponsored by Trutino Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single agent via intravenous infusion on Days 1 and 15 of a 28-day cycle. Up to approximately 50 patients will be enrolled in this study.

Conditions Studied

Advanced Solid Tumors Metastatic Solid Tumors

Interventions

  • DRUG ODC-IL2

Study Locations (1)

Arizona

  • HonorHealth - Scottsdale

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-12-30
Est. Completion 2027-03
Phase Phase 1

Sponsor

Trutino Biosciences

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06770764

The ClinicalTrials.gov registry entry for NCT06770764 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (75% lower). The listed sponsor is Trutino Biosciences, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ODC-IL2 is the first listed.

NCT06770764 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT06770764 about?

NCT06770764 is a clinical study titled "Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors". This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single ...

What is the current status of trial NCT06770764?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-12-30. Estimated completion is 2027-03.

What conditions does trial NCT06770764 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Metastatic Solid Tumors.

What interventions are being tested in trial NCT06770764?

The interventions under investigation include: ODC-IL2 (DRUG).

Who is sponsoring clinical trial NCT06770764?

This trial is sponsored by Trutino Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06770764 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Metastatic Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.